[{"address1": "630 West Germantown Pike", "address2": "Suite 215", "city": "Plymouth Meeting", "state": "PA", "zip": "19462", "country": "United States", "phone": "484 539 9800", "website": "https://www.harmonybiosciences.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.", "fullTimeEmployees": 246, "companyOfficers": [{"maxAge": 1, "name": "Mr. Jeffrey S. Aronin", "age": 55, "title": "Founder & Non-Executive Chairman", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 185667, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jeffrey M. Dayno M.D.", "age": 66, "title": "President, CEO & Director", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 1263419, "exercisedValue": 0, "unexercisedValue": 1516890}, {"maxAge": 1, "name": "Mr. Sandip S. Kapadia CPA, M.B.A.", "age": 53, "title": "Executive VP, Chief Administrative Officer & CFO", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 813524, "exercisedValue": 0, "unexercisedValue": 517069}, {"maxAge": 1, "name": "Dr. Kumar  Budur M.D., M.S.", "title": "Executive VP and Chief Medical & Scientific Officer", "fiscalYear": 2023, "totalPay": 760814, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jeffrey  Dierks M.B.A.", "age": 51, "title": "Executive VP & Chief Commercial Officer", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 830749, "exercisedValue": 0, "unexercisedValue": 412005}, {"maxAge": 1, "name": "Mr. Andrew  Serafin J.D., M.B.A.", "age": 48, "title": "Executive VP & Chief Strategy Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 647425, "exercisedValue": 0, "unexercisedValue": 2916344}, {"maxAge": 1, "name": "Mr. David  Bradshaw", "title": "Head of Technical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Brennan  Doyle", "title": "VP & Head of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christian  Ulrich", "title": "General Counsel & Corporate Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tricia  Glover", "title": "Chief Compliance Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1727740800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 34.97, "open": 35.13, "dayLow": 34.82, "dayHigh": 35.43, "regularMarketPreviousClose": 34.97, "regularMarketOpen": 35.13, "regularMarketDayLow": 34.82, "regularMarketDayHigh": 35.43, "beta": 0.734, "trailingPE": 18.158974, "forwardPE": 10.414705, "volume": 671222, "regularMarketVolume": 671222, "averageVolume": 433740, "averageVolume10days": 584500, "averageDailyVolume10Day": 584500, "marketCap": 2012516736, "fiftyTwoWeekLow": 18.79, "fiftyTwoWeekHigh": 40.6, "priceToSalesTrailing12Months": 3.0673513, "fiftyDayAverage": 36.3701, "twoHundredDayAverage": 32.655, "currency": "USD", "enterpriseValue": 1854670336, "profitMargins": 0.17527, "floatShares": 34658964, "sharesOutstanding": 56834700, "sharesShort": 8538118, "sharesShortPriorMonth": 8755100, "sharesShortPreviousMonthDate": 1724976000, "dateShortInterest": 1727654400, "sharesPercentSharesOut": 0.15020001, "heldPercentInsiders": 0.19750999, "heldPercentInstitutions": 0.94155, "shortRatio": 17.7, "shortPercentOfFloat": 0.6707, "bookValue": 9.476, "priceToBook": 3.7368088, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "earningsQuarterlyGrowth": -0.662, "netIncomeToCommon": 114993000, "trailingEps": 1.95, "forwardEps": 3.4, "pegRatio": 0.68, "enterpriseToRevenue": 2.827, "enterpriseToEbitda": 9.159, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "HRMY", "underlyingSymbol": "HRMY", "shortName": "Harmony Biosciences Holdings, I", "longName": "Harmony Biosciences Holdings, Inc.", "firstTradeDateEpochUtc": 1597843800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "13b9f8e2-d6d9-3fe8-a427-d46e3c835902", "gmtOffSetMilliseconds": -14400000, "currentPrice": 35.41, "targetHighPrice": 56.0, "targetLowPrice": 28.0, "targetMeanPrice": 44.13, "targetMedianPrice": 47.5, "recommendationMean": 2.3, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 346910016, "totalCashPerShare": 6.104, "ebitda": 202500992, "totalDebt": 189062000, "quickRatio": 2.934, "currentRatio": 3.127, "totalRevenue": 656108992, "debtToEquity": 35.104, "revenuePerShare": 11.325, "returnOnAssets": 0.13754, "returnOnEquity": 0.22465, "freeCashflow": 159803872, "operatingCashflow": 213523008, "earningsGrowth": -0.643, "revenueGrowth": 0.288, "grossMargins": 0.79413, "ebitdaMargins": 0.30864, "operatingMargins": 0.12358, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-21"}]